
    
      Participants will be randomized into one of 2 groups to receive either a dose of the TdcP-IPV
      on Day 0 (visit 1) and Hepatitis B vaccine on subsequent visits 2, 3 and 4 (Group 1); or no
      vaccination on Day 0, concomitant administration of TdcP-IPV and Hepatitis B vaccine on Day
      28 (Visit 2) and Hepatitis B vaccine on subsequent visits 3 and 4 (Group 2).

      All participants will be followed up for immunogenicity and safety
    
  